P Abrams1. 1. Bristol Urological Institute, Southmead General Hospital, Westbury-on-Trym, UK.
Abstract
OBJECTIVES: Urodynamic investigations provide an objective, quantitative evaluation of urinary function in patients with benign prostatic obstruction (BPO). The effects of doxazosin, a selective alpha 1-adrenoceptor antagonist, on urodynamic measurements were investigated in three double-blind, placebo-controlled clinical studies of the treatment of BPO. METHODS:302 normotensive and mildly hypertensive men with BPO were evaluated. Patients were randomized to receive doxazosin (1-4 mg o.d.) or placebo for 4-29 weeks. RESULTS:Doxazosin significantly improved free urinary flow rates compared with placebo. Urodynamic studies confirmed that doxazosin was effective in improving urinary flow, and also showed a reduction in detrusor pressure, resulting in decreased voiding time and increased voided volume. Analysis of pressure-flow data demonstrated a significant reduction in a measure of urethral resistance in doxazosin-treated patients. CONCLUSION: These results indicate that doxazosin is an important treatment option for patients with troublesome lower urinary tract symptoms and BPO.
RCT Entities:
OBJECTIVES: Urodynamic investigations provide an objective, quantitative evaluation of urinary function in patients with benign prostatic obstruction (BPO). The effects of doxazosin, a selective alpha 1-adrenoceptor antagonist, on urodynamic measurements were investigated in three double-blind, placebo-controlled clinical studies of the treatment of BPO. METHODS: 302 normotensive and mildly hypertensivemen with BPO were evaluated. Patients were randomized to receive doxazosin (1-4 mg o.d.) or placebo for 4-29 weeks. RESULTS:Doxazosin significantly improved free urinary flow rates compared with placebo. Urodynamic studies confirmed that doxazosin was effective in improving urinary flow, and also showed a reduction in detrusor pressure, resulting in decreased voiding time and increased voided volume. Analysis of pressure-flow data demonstrated a significant reduction in a measure of urethral resistance in doxazosin-treated patients. CONCLUSION: These results indicate that doxazosin is an important treatment option for patients with troublesome lower urinary tract symptoms and BPO.